Comparing the current results to its competitors, Intra Cellular Therapies Inc reported Revenue increase in the 4 quarter 2024 by 50.81 % year on year. The sales growth was above Intra Cellular Therapies Inc 's competitors' average revenue growth of 18.27 %, achieved in the same quarter.
Intra cellular Therapies Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 317.04 %
Intra Cellular Therapies Inc 's Comment on Competition and Industry Peers
The company operates in a highly competitive environment that includes pharmaceutical and biotechnology firms, academic and research institutions, and governmental agencies worldwide. Its product CAPLYTA, indicated for the treatment of schizophrenia and bipolar depression, competes with branded medications such as Vraylar (AbbVie), Rexulti (Otsuka Pharmaceutical), Lybalvi (Alkermes), Fanapt (Vanda Pharmaceuticals), and Cobenfy (Bristol Myers Squibb). CAPLYTA and its product candidates also face competition from various generic antipsychotic drugs, including aripiprazole, clozapine, haloperidol, lurasidone, olanzapine, paliperidone, quetiapine/XR, and risperidone.
Due to outstanding performance in Overall company, revenue grew by 50.81 % Intra cellular Therapies Inc improved its market share, to approximately 0.32 %.
Publicly Traded Peers of Intra cellular Therapies Inc
Xenon Pharmaceuticals Inc Share Performance
+11.77%
This Quarter
Xenon Pharmaceuticals Inc
Profile
Xenon Pharmaceuticals Inc operates in the biopharmaceutical industry, with a focus on discovering and developing innovative therapeutics. Their business model centers around leveraging their proprietary discovery platform to identify and advance potential drug candidates to address unmet medical needs. Through collaborations, licensing agreements, and internal development efforts, Xenon aims to bring new treatments to patients and create value for their stakeholders.
Minerva Neurosciences Inc is a biopharmaceutical company that primarily focuses on the development and commercialization of innovative therapies for central nervous system disorders. They aim to identify potential drug candidates, conduct clinical trials, and collaborate with partners to bring novel treatments to market.
Marinus Pharmaceuticals Inc operates on a business model centered around developing and commercializing innovative therapeutics for rare neurological disorders.
Milestone Pharmaceuticals Inc. is a pharmaceutical company that focuses on developing and commercializing innovative therapies for cardiovascular diseases. Their business model revolves around identifying unmet medical needs in the cardiovascular space and leveraging their expertise in drug development to create novel treatments. By conducting rigorous research, clinical trials, and collaborations, Milestone Pharmaceuticals aims to bring effective and safe medications to market, positively impacting patients' lives.
Longboard Pharmaceuticals Inc is a biotechnology company focused on the discovery and development of therapies for neurological disorders. Their business model revolves around conducting comprehensive research, identifying promising drug candidates, and advancing them through preclinical and clinical trials. With a focus on innovative approaches and strategic partnerships, Longboard aims to ultimately bring safe and effective treatments to patients in need.
Sources:
Intra cellular Therapies Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Intra cellular Therapies Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
